leniolisib

Key facts

Mechanism of action

PI3-kinase p110-delta subunit inhibitor

Primary target: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

Approval history

1. CDZ173/Leniolisib, CDZ173/Leniolisib Phase 3 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome
2. LE 3302 Phase 3 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome
3. LE 7X01 Phase 2 · Pharming Technologies · primary immunodeficiency
4. LE 8201 Phase 2 · Pharming Technologies · Common variable immunodeficiency
5. LE 1102 Phase 1 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome
6. LE 5101 Phase 1 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome
7. LE 6101 Phase 1 · Pharming Technologies · Activated Phosphoinositide 3-Kinase Delta Syndrome

1. idelalisib Antineoplastic and immunomodulating agents (L01)
2. leniolisib phosphate PI3-kinase p110-delta subunit inhibitor
3. parsaclisib Antineoplastic and immunomodulating agents (L01)

Frequently asked questions